A22-NOI.pdf

The Centers for Disease Control and Prevention (CDC), Division of High-Consequence Pathogens and

Pathology (DHCPP), intends to award a sole source, firm-fixed-price contract to Northeast BioLab, located at 35 Wirth Ave, Hamden, Connecticut, 06518. The purpose of this requirement is to conduct pharmacokinetic studies and analysis of black-tailed prairie dog samples. Specifically, the objective is to determine whether the cyclosporin A (CSA) derivatives, Alisporivir and NIM811, can achieve appropriate plasma drug concentrations at specific doses within CAST/EiJ mice.

This acquisition is being conducted under the authority of FAR 13.106-1(b)(1) and 10 U.S.C. 2304(c)(1), which permits soliciting from a single source when only one responsible source and no other supplies or services will satisfy agency requirements.

This notice is not a request for competitive quotations. However, interested parties may submit a capability statement or proposal for consideration. All responses received by 10:00 a.m. Eastern

Standard Time on August 12, 2025 will be reviewed. The Government reserves the right to make a determination not to compete this proposed contract based on the information received. Responses will be evaluated solely to determine whether to conduct a competitive procurement.

Responses or inquiries should be submitted via email to Ashley Williams at dal3@cdc.gov no later than

10:00 a.m. EST on Tuesday, August 12, 2025.